Drugs / EDI048
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05275855 | Apr 2022 → Dec 2024 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07249463 | Dec 2025 → Mar 2027 expected | cryptosporidiosis | Novartis Pharmaceuticals | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EDI048 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07249463 ↗ |
| Route | Oral | “EDI048 administered orally” NCT05275855 ↗ |